​

Funding Round

Venture Round - Veralox Therapeutics

Venture Round - Veralox Therapeutics

Investment Firm

Overview

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.

Announced Date

Jun 20, 2023

Closed on Date

Jun 20, 2023

Funding Type

Series Unknown

Highlights

Location

United States, North America

Social

Investor Lead

Pappas Capital

Pappas Capital

Pappas Capital is a early_stage_venture and late_stage_venture firm.

NYBC Ventures

NYBC Ventures

NYBC Ventures is a early_stage_venture and late_stage_venture and seed firm.

Participant Investors

6

Investor Name
Participant InvestorPappas Capital
Participant InvestorJDRF T1D Fund
Participant InvestorGenesys Capital
Participant InvestorSanofi Ventures
Participant InvestorHatteras Venture Partners

Round Details and Background

Veralox Therapeutics raised $24000000 on 2023-06-20 in Venture Round

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Sep 05, 2019
Seed Round - Veralox Therapeutics
8-5.4M
Jun 16, 2021
Series A - Veralox Therapeutics
10-16.6M
Jun 20, 2023
Venture Round - Veralox Therapeutics
6-24.0M
May 22, 2019
Debt Financing - Veralox Therapeutics
-1.5M

Recent Activity

There is no recent news or activity for this profile.